Effects of daily teriparatide, weekly high-dose teriparatide, or bisphosphonate on cortical and trabecular bone of vertebra and proximal femur in postmenopausal women with fragility fracture: Sub-analysis by quantitative computed tomography from the TERABIT study

Bone. 2024 Oct:187:117189. doi: 10.1016/j.bone.2024.117189. Epub 2024 Jul 2.

Abstract

Purpose: The effects of daily teriparatide (D-PTH, 20 μg/day), weekly high-dose teriparatide (W-PTH, 56.5 μg/week), or bisphosphonate (BP) on the vertebra and proximal femur were investigated using quantitative computed tomography (QCT).

Methods: A total of 131 postmenopausal women with a history of fragility fractures were randomized to receive D-PTH, W-PTH, or bisphosphonate (oral alendronate or risedronate). QCT were evaluated at baseline and after 18 months of treatment.

Results: A total of 86 participants were evaluated by QCT (Spine: D-PTH: 25, W-PTH: 21, BP: 29. Hip: PTH: 22, W-PTH: 21, BP: 32. Dropout rate: 30.5 %). QCT of the vertebra showed that D-PTH, W-PTH, and BP increased total vBMD (+34.8 %, +18.2 %, +11.1 %), trabecular vBMD (+50.8 %, +20.8 %, +12.2 %), and marginal vBMD (+20.0 %, +14.0 %, +11.5 %). The increase in trabecular vBMD was greater in the D-PTH group than in the W-PTH and BP groups. QCT of the proximal femur showed that D-PTH, W-PTH, and BP increased total vBMD (+2.8 %, +3.6 %, +3.2 %) and trabecular vBMD (+7.7 %, +5.1 %, +3.4 %), while only W-PTH and BP significantly increased cortical vBMD (-0.1 %, +1.5 %, +1.6 %). Although there was no significant increase in cortical vBMD in the D-PTH group, cortical bone volume (BV) increased in all three treatment groups (+2.1 %, +3.6 %, +3.1 %).

Conclusions: D-PTH had a strong effect on trabecular bone of vertebra. Although D-PTH did not increase cortical BMD of proximal femur, it increased cortical BV. W-PTH had a moderate effect on trabecular bone of vertebra, while it increased both cortical BMD and BV of proximal femur. Although BP had a limited effect on trabecular bone of vertebra compared to teriparatide, it increased both cortical BMD and BV of proximal femur.

Keywords: High-dose teriparatide; Quantitative computed tomography; Teriparatide; Weekly teriparatide.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Bone Density / drug effects
  • Bone Density Conservation Agents / administration & dosage
  • Bone Density Conservation Agents / therapeutic use
  • Cancellous Bone* / diagnostic imaging
  • Cancellous Bone* / drug effects
  • Cancellous Bone* / pathology
  • Cortical Bone / diagnostic imaging
  • Cortical Bone / drug effects
  • Cortical Bone / pathology
  • Diphosphonates* / administration & dosage
  • Diphosphonates* / pharmacology
  • Diphosphonates* / therapeutic use
  • Female
  • Femur* / diagnostic imaging
  • Femur* / drug effects
  • Femur* / pathology
  • Fractures, Bone / diagnostic imaging
  • Humans
  • Middle Aged
  • Postmenopause* / drug effects
  • Spine / diagnostic imaging
  • Spine / drug effects
  • Teriparatide* / administration & dosage
  • Teriparatide* / pharmacology
  • Teriparatide* / therapeutic use
  • Tomography, X-Ray Computed*

Substances

  • Teriparatide
  • Diphosphonates
  • Bone Density Conservation Agents